| 21-1567 |
Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc. |
Federal Circuit |
2022-06-15 |
Denied |
Amici (2) |
35-usc-112 effective-dose efficacy-requirement federal-circuit multiple-sclerosis patent patent-law patent-specification statutory-interpretation written-description |
Is 35 U.S.C. § 112's written-description requirement met when the specification describes the invention? |
| 21-7010 |
Jabari J. Johnson v. James Johnson |
Tenth Circuit |
2022-01-31 |
Denied |
IFP |
35-usc-112 federal-circuit patent patent-act standing written-description |
Whether the U.S. Court of Appeals for the Federal Circuit erred in its interpretation of the Patent Act's written description requirement under 35 U.S… |
| 21-757 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2021-11-22 |
Judgment Issued |
CVSGAmici (33)Response RequestedRelisted (4) |
35-usc-112 claim-construction claim-scope enablement enablement-requirement invention-disclosure judicial-review patent patent-law statutory-interpretation undue-experimentation written-description |
Whether enablement is a question of fact or law |
| 21-413 |
Infinity Computer Products, Inc. v. Oki Data Americas, Inc. |
Federal Circuit |
2021-09-15 |
Denied |
Response RequestedResponse WaivedRelisted (2) |
35-usc-112 claim-construction claim-interpretation definiteness-standard expert-testimony indefiniteness patent patent-law patent-specification person-skilled-in-the-art prosecution-history |
Whether a patent claim is indefinite under § 112, ¶ 2, if conflicting positions about a claim term arise during the patent prosecution process, even i… |
| 21-170 |
Rain Computing, Inc. v. Samsung Electronics America, Inc., et al. |
Federal Circuit |
2021-08-05 |
Denied |
|
35-usc-112 35-usc-112f claim-construction federal-circuit indefiniteness nautilus-standard nautilus-v-biosig patent patent-law statutory-interpretation |
Whether a patent claim may be invalidated for indefiniteness |
| 20-7267 |
Kevin L. Martin v. Cathleen Capron, et al. |
Seventh Circuit |
2021-03-01 |
Dismissed |
Response WaivedIFP |
35-usc-112 court-of-appeals enablement invention patent prior-art |
Whether the court of appeals erred in finding that the claimed invention meets the enablement requirement of 35 U.S.C. § 112 |
| 20-863 |
Akeva L.L.C. v. Nike, Inc., et al. |
Federal Circuit |
2020-12-30 |
Denied |
Amici (1)Response WaivedRelisted (2) |
35-usc-112 claim-construction claim-interpretation federal-circuit-split innovation-goals judicial-precedent patent-claim-construction patent-law patent-property-rights predictability property-rights public-notice |
Whether the Federal Circuit's 'heavy presumption' line of cases or its 'holistic' line should govern claim construction |
| 20-88 |
HZNP Finance Limited, et al. v. Actavis Laboratories UT, Inc. |
Federal Circuit |
2020-07-29 |
Denied |
Response RequestedResponse WaivedRelisted (2) |
35-usc-112 claim-construction consisting-essentially-of nautilus-v-biosig patent patent-act patent-claim patent-validity reasonable-certainty statutory-interpretation transitional-phrase |
Whether the 'basic and novel properties' identified in connection with a patent claim's transitional phrase 'consisting essentially of' must independe… |
| 19-8094 |
Caleb S. Motupalli v. Andrei Iancu, Director, United States Patent and Trademark Office |
Federal Circuit |
2020-03-24 |
Denied |
Response WaivedIFP |
35-usc-112 america-invents-act enablement interdisciplinary-invention interdisciplinary-team patent-enablement patent-examination patent-specification pre-aia pro-se single-skilled-person waiver |
Does the Leahy-Smith America Invents Act (AIA) permit the retroactive application of a scintilla of inadequacy in Pre-AIA to overturn precedent by ins… |
| 19-1131 |
Actavis Laboratories FL, Inc. v. Nalpropion Pharmaceuticals LLC |
Federal Circuit |
2020-03-16 |
Denied |
Amici (1) |
35-usc-112 claim-construction federal-circuit patent-claims patent-law patent-law-35-usc-112 patent-specification patent-validity statutory-interpretation written-description written-description-requirement |
Whether § 112 requires a patent's specification to contain a written description of all of the limitations of a patent's claims, not just a 'substanti… |
| 19-1073 |
Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., et al. |
Federal Circuit |
2020-03-02 |
Denied |
Response Waived |
35-usc-112 35-usc-282 clear-and-convincing-standard enablement inoperability non-enabled-claims patent-law patent-validity presumption-of-validity statutory-interpretation unpredictability |
Whether patent claims that cover a class may be invalidated as non-enabled under 35 U.S.C. § 112 based on a finding of high unpredictability in the ar… |
| 19-584 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. |
Federal Circuit |
2019-11-04 |
Denied |
Response Waived |
35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description |
Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a… |
| 19-211 |
Time Warner Cable, Inc., et al. v. Sprint Communications Company, L.P. |
Federal Circuit |
2019-08-19 |
Denied |
Amici (1) |
35-usc-112 35-usc-112a 35-usc-284 apportionment federal-circuit garretson-v-clark patent-claims patent-damages patent-infringement patent-validity reasonable-royalty written-description |
Whether the Federal Circuit erred by affirming a damages award based on unapportioned end-user service revenues |
| 18-1515 |
Eli Lilly and Company v. Erfindergemeinschaft UroPep GbR |
Federal Circuit |
2019-06-06 |
Denied |
Amici (3)Response RequestedResponse WaivedRelisted (2) |
35-usc-112 ariad-pharmaceuticals claim-construction enablement functional-claiming halliburton-oil-well-cementing halliburton-oil-well-cementing-co-v-walker halliburton-precedent patent-claims patent-eligibility patent-law point-of-novelty single-step-claim written-description |
Whether a single-step patent claim that describes its point of novelty solely in functional terms violates the rule against functional claiming |
| 18-127 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2018-07-27 |
Denied |
Amici (1)Response RequestedRelisted (2) |
35-usc-112 biotechnology enablement federal-circuit innovation patent-law possession statutory-interpretation written-description |
Whether the standard for determining the adequacy of the 'written description of the invention' should be as the statute says—that the description mus… |